Drugs & Targets FDA approves crizanlizumab-tmca for sickle cell disease November 22, 2019Vol.45 No.44
Drugs & Targets European Commission approves two regimens of Keytruda for front-line metastatic, unresectable HNSCC November 22, 2019Vol.45 No.44
Drugs & Targets European Commission grants marketing authorization for Darzalex + lenalidomide and dexamethasone in frontline MM November 22, 2019Vol.45 No.44
Drugs & Targets Japan grants approval of Myriad Genetics’ BRACAnalysis Diagnostic System for breast cancer patients November 22, 2019Vol.45 No.44
Drugs & Targets FDA grants Breakthrough Device Designation for Exact Sciences blood-based test for detection of HCC November 15, 2019Vol.45 No.43
Drugs & Targets FDA accepts BMS application for Opdivo + Yervoy for liver cancer November 15, 2019Vol.45 No.43
Drugs & Targets Janssen seeks FDA approval for Imbruvica + rituximab for previously untreated patients with CLL November 15, 2019Vol.45 No.43
Drugs & Targets Canada approves Imbruvica combination for CLL indication November 15, 2019Vol.45 No.43
Drugs & Targets UroGen receives rights to Zalifrelimab for intravesical treatment of urinary tract cancers November 15, 2019Vol.45 No.43
